![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Repligen Partners for Bipolar Disorder Clinical Trial Funds
Repligen Partners for Bipolar Disorder Clinical Trial Funds
March 15, 2005
Biopharmaceutical company Repligen Corp. and Stanley Medical Research Institute entered a development agreement that gives Repligen funding for a Phase I clinical trial for a treatment of bipolar disorder, the company announced. The clinical trial will assess the oral bioavailability of Repligen's proprietary formulation of uridine. The amount of the grant for the Waltham company was not disclosed.
Boston Business Journal (http://www.bizjournals.com/boston/stories/2005/03/14/daily7.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct